Institutional Ownership
Monte Rosa Therapeutics Inc
CUSIP 61225M102COMGLUEQ1 2026
13D / 13G Filings
48
Schedule 13D/13G on record
Beneficial Filers
16
Distinct reporting persons
Largest Stake
15.3%
Max % of class reported
Institutional Holders
183
13F filers (latest quarter)
Beneficial Owners — Schedule 13D / 13G
48 filings · latest Feb 17, 2026
| # | Filed | Reporting Person | Form | % of Class | Shares | Filing |
|---|---|---|---|---|---|---|
| 1 | Feb 17, 2026 | Baker Bros. Advisors LP | 13G/A | 6.7% | 4.35M | SEC |
| 2 | Feb 17, 2026 | Biotechnology Value Fund L P | 13G/A | 5.9% | 3.84M | SEC |
| 3 | Jan 21, 2026 | Adam Goulburn | 13G/A | 8.7% | 5.66M | SEC |
| 4 | Jan 9, 2026 | Versant Venture Capital Vi, L.P. | 13D/A | 3.4% | — | SEC |
| 5 | Nov 14, 2025 | Avoro Capital Advisors LLC | 13G/A | — | 49 | SEC |
| 6 | Nov 14, 2025 | T. Rowe Price Associates, Inc. | 13G/A | 7.5% | 4.64M | SEC |
| 7 | Nov 12, 2025 | Versant Venture Capital Vi, L.P. | 13D/A | 5.1% | — | SEC |
| 8 | Oct 31, 2025 | The Vanguard Group | 13G/A | 4.8% | 2.99M | SEC |
| 9 | Oct 17, 2025 | Tcg Crossover Gp II, LLC | 13G | 11.0% | 4.43M | SEC |
| 10 | Oct 3, 2025 | Adam Goulburn | 13G | 7.7% | 4.76M | SEC |
38 more beneficial-ownership filings on Premium
See the full Schedule 13D/13G history for Monte Rosa Therapeutics Inc.
Unlock full historyTop Institutional Holders (13F)
Largest reported positions · latest quarter
| # | Fund | Shares | Value |
|---|---|---|---|
| 1 | Nea Management Company, LLC | 7.69M | $126.54M |
| 2 | Blackrock, Inc. | 5.64M | $92.74M |
| 3 | Tcg Crossover Management, LLC | 4.62M | $76.03M |
| 4 | Bvf Inc/Il | 4.46M | $73.38M |
| 5 | Baker Bros. Advisors LP | 4.35M | $71.49M |
| 6 | Suvretta Capital Management, LLC | 4.23M | $69.53M |
| 7 | Vestal Point Capital, LP | 3.60M | $59.28M |
| 8 | State Street Corp | 3.35M | $55.17M |
| 9 | Braidwell LP | 3.21M | $52.75M |
| 10 | Versant Venture Management, LLC | 3.18M | $52.32M |